About Belyntic Exit

Modern therapeutic approaches face the challenge to combine efficacy, low undesired side effects and reasonable pricing. Therefore, drug substances become more and more complex, therapies become more personalized while overall life-cycle costs from drug discovery up to the manufacturing of the final therapeutic are on trial.
Peptides – or short proteins - represent a promising therapeutic class, and Belyntic’s PEC technology offers an innovative solution for their manufacturing. The linker-based approach enables parallel, efficient and highly selective purification and modification of chemically synthesized peptides. Belyntic offers kit products as well as cooperation projects and custom services for research institutions, custom peptide manufacturers as well as biotech and pharma companies.

Press releases

16. September 2019

Chemistry-for-Healthcare Start-up secures seed investment from Investitionsbank Berlin (IBB) and High-Tech Gründerfonds (HTGF)

Belyntic, a Berlin-based chemistry-for-healthcare startup and developer of the Peptide Easy Clean (PEC) purification technology, has completed its seed financing round amounting to €1.3 million. The funding is led by the Investitionsbank Berlin (IBB), with the High-Tech Gründerfonds (HTGF) also climbing on board alongside business angel Till Knorr. Belyntic's potential in the field of peptide therapeutics was immediately recognized by major industry insiders after its foundation in May 2018.

Info & Contact

+49 30 8104 1113


Belyntic GmbH
Building 8.15, Room 616
Richard-Willstaetter-Str. 11
12489 Berlin, Germany

In portfolio

08. Apr 2019 – 10. Jul 2023



Ulrike Kalapis

Investment Manager